Abstract
2046 Background: Systemic treatment options are limited for patients with recurrent meningioma. VEGF and PDGF promote angiogenesis and cellular proliferation. PTK-787 is an oral inhibitor of VEGF and PDGF receptors. The primary endpoint was to determine overall response rate. Secondary endpoints were 6-month progression-free survival (PFS-6) and overall survival. Methods: Patients (pts) with histologically confirmed recurrent WHO Grade 2 or 3 meningioma were eligible. Pts had no limit on prior therapies though must have included surgery and radiotherapy, a KPS ≥60, and were not taking enzyme inducing anticonvulsants. PTK-787 administration began at 250 mg BID and increased by 250 mg/day weekly to a dose of 500 mg BID. Clinical examinations were performed after each 4-week cycle and imaging every 8 weeks. Responses were graded using modified Macdonald criteria. Results: 21 pts were treated: 14 grade 2 and 7 grade 3 meningiomas (11 men; 10 women). Median age was 59 (29-88) years. Median KPS was 80 (60-100). Median number of cycles was 2 (range < 1-14) with one patient remaining on treatment. Main toxicities were transaminase elevation grade 4 (n=1) and 3 (n=3), fatigue grade 3 (n=4) and rash grade 3 (n=2). 3 pts were withdrawn early due to toxicity and were not evaluable for response. Best response in the remaining 17 pts was PR (n=1; 5.8%), SD (n= 12; 70.6%) and PD (n = 5; 29.4%). Overall PFS-6 and 12 was 37.5% and 12.5%; median time to progression was 3.7 m grade 2 and 3.6 m grade 3 months among the 21 pts (intent to treat). Median overall survival was 22.9 m for grade 2 and 19.6 m for grade 3. Conclusions: The combination VEGF/PDGF inhibition in pts with recurrent or progressive high-grade meningiomas can lead to disease stabilization. Targeted therapy may have a better role than cytotoxic therapies given the limited activity of available agents and suggest further studies with VEGF signaling pathway inhibition are warranted.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
